益生菌用于小儿肠易激综合征：一项随机对照临床试验。
Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial.
作者信息
Kianifar Hamidreza, Jafari Seyed Ali, Kiani Mohammadali, Ahanchian Hamid, Ghasemi Seyed Vahid, Grover Zubin, Mahmoodi Leili Zarif, Bagherian Rita, Khalesi Maryam
机构信息
MD, Associate Professor, Department of Pediatric Gastroenterology, Ghaem Medical Center, Mashhad University of Medical Sciences, Mashhad, Iran.
MD, Associate Professor, Department of Pediatric Immunology and Allergy, Ghaem Medical Center, Mashhad University of Medical Sciences, Mashhad, Iran.
出版信息
Electron Physician. 2015 Sep 16;7(5):1255-60. doi: 10.14661/1255. eCollection 2015 Sep.
BACKGROUND
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in children. Recently, probiotics have been suggested as a treatment option for gastrointestinal disorders. The most effective species and the most appropriate doses are still unknown.
OBJECTIVE
The aim of this study was to assess the effects of Lactobacillus GG (LGG) for treating IBS in pediatric patients.
METHODS
In a controlled, double blind, randomized trial, patients with IBS diagnosed by Rome III criteria from August 2012 to September 2012 at Dr. Sheikh Hospital, Mashhad University of Medical Sciences, Iran, were assigned to one of two groups, i.e., intervention and control groups. For four weeks, the intervention group received a probiotic in capsule form that contained LGG at a concentration of 1×10(10) cfu/ml bacteria. For the same period, the control group received a placebo capsule that had the same shape and color but only contained inulin, which also was present in the LGG capsules. The primary outcome was any change in the severity of the patients' pain, and we used a five-point Likert scale to evaluate the severity of their pain. Secondary outcomes were ghanges of the functional scale, stool patterns, and associated problems.
RESULTS
Fifty-two patients participated in the study, and 26 patients were assigned randomly to each of the two groups. The severity of the patients' pain decreased significantly in the intervention group after one, two, three, and four weeks of treatment, as indicated by P-values of 0.01, 0.00, 0.00, and 0.00, respectively. Also, there was significant improvement in the functional scale after two weeks of treatment (P-value ≤ 0.00).
CONCLUSION
Lactobacillus GG at a concentration of 1×10(10) cfu/ml for a period of four weeks can lessen the severity of the patients' pain and improve the functional scale in patients with irritable bowel syndrome. Probiotics can have therapeutic effects for IBS patients.
背景
肠易激综合征（IBS）是儿童常见的胃肠道疾病。近来，益生菌被提议作为胃肠道疾病的一种治疗选择。最有效的菌株和最合适的剂量仍不明确。
目的
本研究旨在评估鼠李糖乳杆菌GG（LGG）治疗儿科肠易激综合征患者的效果。
方法
在一项对照、双盲、随机试验中，2012年8月至2012年9月期间在伊朗马什哈德医科大学谢赫医院依据罗马III标准诊断为肠易激综合征的患者被分为两组，即干预组和对照组。四周内，干预组接受含浓度为1×10(10) cfu/ml细菌的LGG的胶囊形式益生菌。同期，对照组接受形状和颜色相同但仅含菊粉的安慰剂胶囊，菊粉也存在于LGG胶囊中。主要结局是患者疼痛严重程度的任何变化，我们用五点李克特量表评估其疼痛严重程度。次要结局是功能量表、排便模式及相关问题的变化。
结果
52例患者参与研究，两组各随机分配26例患者。干预组治疗1周、2周、3周和4周后患者疼痛严重程度显著降低，P值分别为0.01、0.00、0.00和0.00。此外，治疗2周后功能量表有显著改善（P值≤0.00）。
结论
浓度为1×10(10) cfu/ml的鼠李糖乳杆菌GG持续四周可减轻肠易激综合征患者的疼痛严重程度并改善功能量表。益生菌对肠易激综合征患者有治疗作用。
Zotero 插件